← All webinar archives

Webinar archive

Targeting Cancer Pathways

Six hour-long talks on the actionable axes of cancer biology — resistance, microenvironment, metabolism, epigenetics, immune checkpoints, and spatial-imaging biomarkers. Each video opens click-to-load to keep this page fast.

Two videos that also appear in the original YouTube playlist (the cellular-mechanisms of the immune response, and the targeted-protein-degradation talk) are catalogued in the Deciphering Disease archive to avoid duplication.

Targeting Cancer Pathways · Cancer Biology

Targeting Cancer Pathways: Tumor Resistance

Acquired and intrinsic resistance to targeted therapy and immunotherapy — gatekeeper mutations (T790M EGFR, T315I ABL), bypass-pathway activation, lineage plasticity, and the persister-cell concept.

Targeting Cancer Pathways · Cancer Biology

Targeting Cancer Pathways: The Tumor Microenvironment

The cellular and matrix ecosystem of tumours — CAFs, hypoxia/HIF, ECM stiffening, the immunosuppressive milieu, and TME-targeted therapeutic strategies (vascular normalisation, anti-CAF).

Targeting Cancer Pathways · Cancer Biology

Targeting Cancer Pathways: Tumor Metabolism and Proliferation

The Warburg effect revisited, glutaminolysis, lipogenic switch, and clinical-pipeline metabolic targets — IDH inhibitors (ivosidenib, enasidenib), glutaminase inhibition, FAS pathway.

Targeting Cancer Pathways · Cancer Biology

Targeting Cancer Pathways: The Epigenetics Question

Epigenetic dysregulation as a cancer driver — DNA methylation, histone marks, BRD4/BET, EZH2, HDAC; clinical context for tazemetostat, vorinostat, and emerging combinations with checkpoint blockade.

Targeting Cancer Pathways · Cancer Biology

Targeting Cancer Pathways: Understanding Immune Checkpoints

PD-1/PD-L1 and CTLA-4 biology, the molecular interface of T-cell suppression, predictive biomarkers (PD-L1 IHC, MSI, TMB), and the next wave of co-inhibitory targets (LAG-3, TIM-3, TIGIT).

Targeting Cancer Pathways · Cancer Biology

Spatial Imaging as a Tool for Discovery of New Candidates to Predict Response to Immunotherapies

Multiplex immunofluorescence, imaging mass cytometry, and spatial transcriptomics for resolving the cellular geography of the tumour-immune interface; biomarker discovery for checkpoint-blockade response.

Cross-references in the course library

Share:XRedditLinkedIn